|
|||
DRUGS & SUPPLEMENTS
|
How long you have been taking the medicine? |
Intravenous solutions containing Dextrose 5% and Sodium Chloride 0.33% are indicated for parenteral replenishment of fluid, minimal carbohydrate calories, and sodium chloride as required by the clinical condition of the patient.
None known.
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
Excessive administration of potassium-free solutions may result in significant hypokalemia.
In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.
The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema.
The risk of dilutional states is inversely proportional to the electrolyte concentrations of administered parenteral solutions. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of such solutions.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid-base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions to patients receiving corticosteroids or corticotropin.
Do not administer unless solution is clear and container is undamaged. Discard unused portion.
Pregnancy Category C. Animal reproduction studies have not been conducted with dextrose or sodium chloride. It is also not known whether dextrose or sodium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose or sodium chloride should be given to a pregnant woman only if clearly needed.
Pediatric Use. The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants, the volume of fluid may affect fluid and electrolyte balance.
Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.
In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
Geriatric Use. An evaluation of current literature revealed no clinical experience identifying differences in response between elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Sodium ions are known to be substantially excreted by the kidney, and the risk of toxic reactions may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. See WARNINGS , PRECAUTIONS , and ADVERSE REACTIONS .
The dose is dependent upon the age, weight and clinical condition of the patient.
As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS .
Drug Interactions
Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix thoroughly and do not store.
To Open:
Tear outer wrap at notch and remove solution container. If supplemental medication is desired, follow directions below before preparing for administration.
To Add Medication
Preparation for Administration
(Use aseptic technique)
WARNING: Do not use flexible container in series connections.
Dextrose 5% and Sodium Chloride 0.33% Injection, USP are supplied in single-dose flexible plastic containers in various sizes and concentrations as shown in the accompanying Table.
| | |||||||||
NDC No. | Product | Dextrose (hydrous) | Sodium Chloride | Sodium Na+ | Chloride Cl¯ | Caloric Value | Tonicity | Osmolarity mOsmol/L (calc) | pH | Container size (mL) |
0409-7924-02 | 5% Dextrose and 0.225% Sodium Chloride Inj., USP | 5 | 0.225 | 38.5 mEq | 38.5 mEq | 170 | Hypertonic | 329 | 4.3 (3.5 to 6.5) | 250 |
0409-7924-03 | 5% Dextrose and 0.225% Sodium Chloride Inj., USP | 5 | 0.225 | 38.5 mEq | 38.5 mEq | 170 | Hypertonic | 329 | 4.3 (3.5 to 6.5) | 500 |
0409-7924-09 | 5% Dextrose and 0.225% Sodium Chloride Inj., USP | 5 | 0.225 | 38.5 mEq | 38.5 mEq | 170 | Hypertonic | 329 | 4.3 (3.5 to 6.5) | 1000 |
0409-7925-02 | 5% Dextrose and 0.3% Sodium Chloride Inj., USP | 5 | 0.3 | 51 mEq | 51 mEq | 170 | Hypertonic | 355 | 4.3 (3.5 to 6.5) | 250 |
0409-7925-03 | 5% Dextrose and 0.3% Sodium Chloride Inj., USP | 5 | 0.3 | 51 mEq | 51 mEq | 170 | Hypertonic | 355 | 4.3 (3.5 to 6.5) | 500 |
0409-7925-09 | 5% Dextrose and 0.3% Sodium Chloride Inj., USP | 5 | 0.3 | 51 mEq | 51 mEq | 170 | Hypertonic | 355 | 4.3 (3.5 to 6.5) | 1000 |
0409-7926-02 | 5% Dextrose and 0.45% Sodium Chloride Inj., USP | 5 | 0.45 | 77 mEq | 77 mEq | 170 | Hypertonic | 406 | 4.3 (3.5 to 6.5) | 250 |
0409-7926-03 | 5% Dextrose and 0.45% Sodium Chloride Inj., USP | 5 | 0.45 | 77 mEq | 77 mEq | 170 | Hypertonic | 406 | 4.3 (3.5 to 6.5) | 500 |
0409-7926-09 | 5% Dextrose and 0.45% Sodium Chloride Inj., USP | 5 | 0.45 | 77 mEq | 77 mEq | 170 | Hypertonic | 406 | 4.3 (3.5 to 6.5) | 1000 |
0409-7941-02 | 5% Dextrose and 0.9% Sodium Chloride Inj., USP | 5 | 0.9 | 154 mEq | 154 mEq | 170 | Hypertonic | 560 | 4.3 (3.5 to 6.5) | 250 |
0409-7941-03 | 5% Dextrose and 0.9% Sodium Chloride Inj., USP | 5 | 0.9 | 154 mEq | 154 mEq | 170 | Hypertonic | 560 | 4.3 (3.5 to 6.5) | 500 |
0409-7941-09 | 5% Dextrose and 0.9% Sodium Chloride Inj., USP | 5 | 0.9 | 154 mEq | 154 mEq | 170 | Hypertonic | 560 | 4.3 (3.5 to 6.5) | 1000 |
Protect from freezing. Store at 20 to 25°C (68 to 77°F).
Revised: June, 2009
Printed in USA EN-2179
Hospira, Inc., Lake Forest, IL 60045 USA
1000 mL
NDC 0409-7924-09
5% DEXTROSE
and 0.225%
SODIUM CHLORIDE
Injection, USP
EACH 100 mL CONTAINS DEXTROSE,
HYDROUS 5 g; SODIUM CHLORIDE
225 mg IN WATER FOR INJECTION.
ELECTROLYTES PER 1000 mL: SODIUM
38.5 mEq; CHLORIDE 38.5 mEq.
329 mOsmol/LITER (CALC).
pH 4.3 (3.5 to 6.5).
ADDITIVES MAY BE INCOMPATIBLE.
CONSULT WITH PHARMACIST, IF
AVAILABLE. WHEN INTRODUCING
ADDITIVES, USE ASEPTIC TECHNIQUE,
MIX THOROUGHLY AND DO NOT STORE.
SINGLE-DOSE CONTAINER. FOR I.V. USE.
USUAL
Dosage: SEE INSERT. STERILE,
NONPYROGENIC. USE ONLY IF
SOLUTION IS CLEAR AND CONTAINER IS
UNDAMAGED. MUST NOT BE USED IN
SERIES CONNECTIONS.
Rx ONLY
3
v
CONTAINS DEHP
Hospira
©HOSPIRA 2004
IM-0159 (10/04)
PRINTED IN USA
HOSPIRA, INC., LAKE FOREST, IL 60045 USA
Depending on the reaction of the Dextrose 5% and Sodium Chloride 0.33% after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Dextrose 5% and Sodium Chloride 0.33% not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.
Is Dextrose 5% and Sodium Chloride 0.33% addictive or habit forming?Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
Visitors | % | ||
---|---|---|---|
> 3 month | 1 | 100.0% |
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Rachana Salvi, MD Pharmacology